



**SUVEN LIFE SCIENCES LTD**

Regd. Off: 8-2-334, SDE Serene Chambers, 6th Floor, Road No.5, Avenue 7, Banjara Hills, Hyderabad - 500 034  
 Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 email: investorservices@suvan.com website: www.suvan.com CIN:  
 L24110TG1989PLC009713

**STATEMENT OF UN-AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED 31st DEC-2018**

*All amounts in Indian Rupees in Lakhs*

Sl. No.	Particulars	For the Quarter Ended			For the Nine Months Ended		For the year Ended
		31-Dec-2018	30-Sep-2018	31-Dec-2017	31-Dec-2018	31-Dec-2017	31-Mar-2018
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
<b>1</b>	<b>Income</b>						
	Revenue from operations	12,902.10	8,952.18	16,365.73	41,020.50	41,153.51	62,525.84
	Other Income	576.20	658.63	328.95	2,047.60	1,404.47	2,327.07
	<b>Total income</b>	<b>13,478.30</b>	<b>9,610.81</b>	<b>16,694.68</b>	<b>43,068.10</b>	<b>42,557.98</b>	<b>64,852.91</b>
<b>2</b>	<b>Expenses</b>						
	a) Cost of materials consumed	6,217.04	4,102.39	5,104.86	14,178.73	13,006.52	17,490.30
	b) Purchases of stock-in-trade	-	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(3,434.32)	(3,525.10)	(185.72)	(4,363.60)	(3,602.25)	(2,120.13)
	d) Employee benefits expense	1,495.42	1,398.33	1,481.60	4,608.57	4,315.58	5,873.50
	e) Finance costs	52.94	59.09	115.16	218.82	335.75	461.11
	f) Depreciation and amortisation expense	560.93	556.05	541.66	1,667.79	1,594.85	2,130.99
	g) Manufacturing Exps	2,704.36	2,493.06	2,379.39	7,482.92	6,670.79	8,821.54
	h) R & D Exps	1,403.11	1,238.73	1,387.83	4,240.71	4,155.15	5,846.66
	i) Other Expenses	956.81	803.29	1,058.62	3,048.91	2,440.34	3,322.37
	<b>Total expenses</b>	<b>9,956.29</b>	<b>7,125.84</b>	<b>11,883.40</b>	<b>31,082.85</b>	<b>28,916.73</b>	<b>41,826.34</b>
<b>3</b>	<b>Profit before exceptional items &amp; Tax (1-2)</b>	<b>3,522.01</b>	<b>2,484.97</b>	<b>4,811.28</b>	<b>11,985.25</b>	<b>13,641.25</b>	<b>23,026.57</b>
<b>4</b>	Exceptional Items	-	-	-	-	-	-
<b>5</b>	<b>Profit before Tax (3-4)</b>	<b>3,522.01</b>	<b>2,484.97</b>	<b>4,811.28</b>	<b>11,985.25</b>	<b>13,641.25</b>	<b>23,026.57</b>
<b>6</b>	Tax Expenses						
	a) Current tax	697.27	513.83	1,014.68	2,460.24	2,739.56	4,756.49
	b) Deferred tax	301.47	170.17	336.78	1,316.56	1,310.07	2,427.35
<b>7</b>	<b>Net Profit/ (Loss) for the period/year(5-6)</b>	<b>2,523.27</b>	<b>1,800.97</b>	<b>3,459.82</b>	<b>8,208.45</b>	<b>9,591.62</b>	<b>15,842.73</b>
<b>8</b>	<b>Other Comprehensive Income</b>						
<b>8.a</b>	(i) Items that will not be reclassified to profit or loss	(10.58)	(10.59)	(3.73)	(31.75)	(11.18)	(42.33)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	3.76	3.67	1.29	11.09	3.87	14.65
<b>8.b</b>	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	<b>Total other Comprehensive Income</b>	<b>(6.82)</b>	<b>(6.92)</b>	<b>(2.44)</b>	<b>(20.66)</b>	<b>(7.31)</b>	<b>(27.68)</b>
<b>9</b>	<b>Total Comprehensive Income for the period (7+8)</b>	<b>2,516.45</b>	<b>1,794.05</b>	<b>3,457.38</b>	<b>8,187.79</b>	<b>9,584.31</b>	<b>15,815.05</b>
<b>10</b>	Paid-up equity share capital (face value of Rs. 1/- each)	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82
<b>11</b>	Other Equity						85,397.16
<b>12</b>	<b>Earning Per Share (EPS) (Face value of Rs.1/- each)</b>						
	a) Basic	1.98	1.41	2.72	6.45	7.54	12.45
	b) Diluted	1.98	1.41	2.72	6.45	7.54	12.45
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	

SEGMENT WISE REVENUE, RESULTS AND TOTAL ASSETS AND LIABILITIES						
PARTICULARS	For the Quarter Ended			For the Nine Months Ended		For the year Ended
	31-Dec-2018	30-Sep-2018	31-Dec-2017	31-Dec-2018	31-Dec-2017	31-Mar-2018
	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
<b>1 SEGMENT REVENUE :-</b>						
a) Manufaturing (CRAMS)	11,508.11	8,087.96	15,693.88	37,620.29	39,051.11	59,687.64
b) Services (DDDSS)	1,393.99	864.22	671.85	3,400.21	2,102.40	2,838.20
c) Research & Development	-	-	-	-	-	-
<b>TOTAL</b>	<b>12,902.10</b>	<b>8,952.18</b>	<b>16,365.73</b>	<b>41,020.50</b>	<b>41,153.51</b>	<b>62,525.84</b>
Less Inter segment Revenue	-	-	-	-	-	-
<b>Net Sales from Operations</b>	<b>12,902.10</b>	<b>8,952.18</b>	<b>16,365.73</b>	<b>41,020.50</b>	<b>41,153.51</b>	<b>62,525.84</b>
<b>2 SEGMENT RESULTS :-</b>						
Profit/(Loss) before tax and interest:						
a) Manufaturing (CRAMS)	4,138.53	3,252.05	6,444.25	14,477.32	17,539.24	28,031.87
b) Services (DDDSS)	785.85	440.57	267.76	1,987.56	992.37	1,428.77
c) Research & Development	(1,403.11)	(1,238.73)	(1,387.83)	(4,240.71)	(4,155.15)	(5,846.66)
<b>TOTAL</b>	<b>3,521.27</b>	<b>2,453.89</b>	<b>5,324.18</b>	<b>12,224.17</b>	<b>14,376.46</b>	<b>23,613.98</b>
Less: i) Interest	31.17	62.29	72.41	129.43	233.71	281.59
ii) Other Un-allocable expenditure/(Income), net	(31.91)	(93.37)	440.49	109.49	501.50	305.82
<b>Total Profit Before Tax</b>	<b>3,522.01</b>	<b>2,484.97</b>	<b>4,811.28</b>	<b>11,985.25</b>	<b>13,641.25</b>	<b>23,026.57</b>
<b>3 SEGMENT ASSETS :</b>						
a) Manufaturing (CRAMS)	64,192.57	57,618.63	56,835.94	64,192.57	56,835.94	52,557.03
b) Services (DDDSS)	5,755.22	3,767.31	4,174.47	5,755.22	4,174.47	4,061.14
c) Research & Development	2,794.09	3,028.20	3,117.69	2,794.09	3,117.69	3,031.96
d) Un allocated	41,584.05	44,219.74	35,007.49	41,584.05	35,007.49	41,234.30
<b>TOTAL</b>	<b>114,325.93</b>	<b>108,633.88</b>	<b>99,135.59</b>	<b>114,325.93</b>	<b>99,135.59</b>	<b>100,884.43</b>
<b>SEGMENT LIABILITIES :</b>						
a) Manufaturing (CRAMS)	11,305.72	9,282.73	9,663.85	11,305.72	9,663.85	8,594.07
b) Services (DDDSS)	690.10	473.46	498.66	690.10	498.66	382.64
c) Research & Development	2,071.66	1,669.94	1,866.63	2,071.66	1,866.63	1,587.28
d) Un allocated	1,053.78	949.14	856.23	1,053.78	856.23	714.79
<b>TOTAL</b>	<b>15,121.26</b>	<b>12,375.27</b>	<b>12,885.37</b>	<b>15,121.26</b>	<b>12,885.37</b>	<b>11,278.78</b>
<p>1). The above financial results were reviewed by Audit Committee of the Board and approved by the Board of Directors' at their Meeting held on 05th February, 2019 and the same reviewed by the Statutory Auditors.</p> <p>2). Effective from 1st April 2018, the company has adopted Ind AS-115, "Revenue from contract with customers". The application of Ind AS-115 does not have any significant impact on recognition and measurement of revenue from operations and other related items in the financial results of the company.</p> <p>3). The Board has declared an Interim Dividend of Rs. 1.50 per equity share (150% of face value of Rs. 1.00/- each) for the financial year 2018-19, The outflow on account of Interim dividend including dividend distribution tax is Rs. 2301.69 lakhs.</p> <p>4). The corresponding previous period figures have been regrouped / reclassified where ever necessary.</p>						
<b>For SUVEN LIFE SCIENCES LIMITED</b>						
				<b>VENKAT JASTI</b>		
Place: Hyderabad				Chairman & CEO		
Date: 05th February, 2019				DIN: 00278028		
<i>We Deliver</i>						